BUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares

Reuters12-15

** Shares of pharmaceutical products and vaccines developer Everest Medicines 1952.HK jump 8.3% to HK$48.54, their highest level since Nov. 14

** Stock set for the biggest one-day pct rise since Aug. 4, on the fourth straight session of gains

** Company said on Monday its key shareholder CBC Group has undertaken to increase its shareholding by not more than 1% in the open-market in next three to six months to signify its strong confidence in company's prospects and development

** Company also says its chairman Wei Fu and three others senior management had on Dec. 12 bought a total 846,659 shares for an aggregate HK$38 mln ($4.88 million), representing an average price of about HK$45 per share

** YTD, stock down 1.5%, while Hang Seng Biotech Index .HSBIO up 71.3%

($1 = 7.7825 Hong Kong dollars)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591769197?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 11:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591769197","market":"fut","top_or_hot":-1,"title":"BUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares </title></head><body><p>** Shares of pharmaceutical products and vaccines developer Everest Medicines <span>1952.HK</span> jump 8.3% to HK$48.54, their highest level since Nov. 14</p><p>** Stock set for the biggest one-day pct rise since Aug. 4, on the fourth straight session of gains</p><p>** Company said on Monday its key shareholder CBC Group has undertaken <span>to increase its shareholding</span> by not more than 1% in the open-market in next three to six months to signify its strong confidence in company's prospects and development</p><p>** Company also says its chairman Wei Fu and three others senior management had on Dec. 12 bought a total 846,659 shares for an aggregate HK$38 mln ($4.88 million), representing an average price of about HK$45 per share</p><p>** YTD, stock down 1.5%, while <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Biotech Index <span>.HSBIO</span> up 71.3%</p><p>($1 = 7.7825 Hong Kong dollars)</p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-15 11:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares </title></head><body><p>** Shares of pharmaceutical products and vaccines developer Everest Medicines <span>1952.HK</span> jump 8.3% to HK$48.54, their highest level since Nov. 14</p><p>** Stock set for the biggest one-day pct rise since Aug. 4, on the fourth straight session of gains</p><p>** Company said on Monday its key shareholder CBC Group has undertaken <span>to increase its shareholding</span> by not more than 1% in the open-market in next three to six months to signify its strong confidence in company's prospects and development</p><p>** Company also says its chairman Wei Fu and three others senior management had on Dec. 12 bought a total 846,659 shares for an aggregate HK$38 mln ($4.88 million), representing an average price of about HK$45 per share</p><p>** YTD, stock down 1.5%, while <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Biotech Index <span>.HSBIO</span> up 71.3%</p><p>($1 = 7.7825 Hong Kong dollars)</p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL1N3XL032:1","article_id":"2591769197","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591769197","pubTimestamp":1765769081,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares ** Shares of pharmaceutical products and vaccines developer Everest Medicines 1952.HK jump 8.3% to HK$48.54, their highest level since Nov. 14** Stock set for the biggest one-day pct rise since Aug. 4, on the fourth straight session of gains** Company said on Monday its key shareholder CBC Group has undertaken to increase its shareholding by not more than 1% in the open-market in next three to six months to signify its strong confidence in company's prospects and development** Company also says its chairman Wei Fu and three others senior management had on Dec. 12 bought a total 846,659 shares for an aggregate HK$38 mln , representing an average price of about HK$45 per share** YTD, stock down 1.5%, while Hang Seng Biotech Index .HSBIO up 71.3%  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1583":"高瓴概念","01952":"云顶新耀","BK1574":"生物医药B类股"},"translate_title":"BUZZ-Everest Medicines创4周新高，成为主要股东，高管买入股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":0.9},"content_text":"BUZZ-Everest Medicines at 4-week high as key shareholder, executives buy shares ** Shares of pharmaceutical products and vaccines developer Everest Medicines 1952.HK jump 8.3% to HK$48.54, their highest level since Nov. 14** Stock set for the biggest one-day pct rise since Aug. 4, on the fourth straight session of gains** Company said on Monday its key shareholder CBC Group has undertaken to increase its shareholding by not more than 1% in the open-market in next three to six months to signify its strong confidence in company's prospects and development** Company also says its chairman Wei Fu and three others senior management had on Dec. 12 bought a total 846,659 shares for an aggregate HK$38 mln ($4.88 million), representing an average price of about HK$45 per share** YTD, stock down 1.5%, while Hang Seng Biotech Index .HSBIO up 71.3%($1 = 7.7825 Hong Kong dollars) (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591769197","isCrawlerRequest":true}